Solid Biosciences Inc (SLDB)

$5.58 +0.11 (2.01%)
Market Cap 426.17M
Revenue (ttm) 0.00
Net Income (ttm) -124.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 301,866
Avg Vol 1,057,980
Day's Range N/A - N/A
Shares Out 77.91M
Stochastic %K 53%
Beta 2.69
Analysts Strong Sell
Price Target $15.23

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
Olg59
Olg59 Jan. 20 at 4:50 PM
$SLDB Brake 6.00, then fly to 10.00 Under 5.70 great entry!
0 · Reply
Jonrenie
Jonrenie Jan. 20 at 9:51 AM
$SLDB keep an eye for more loading opportunities
0 · Reply
LeaRoss
LeaRoss Jan. 19 at 2:50 PM
$SLDB Watching for volume surge, breakout could fuel momentum
1 · Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 17 at 12:08 PM
$SLDB 📈 Technicals are starting to align with a strong fundamental story. Currently testing the upper trendline of a multi-month symmetrical triangle. If this helps, tap @QuantitativeTrading_ As price coils toward the apex, I’m watching for a high-volume breakout above $6.00 — a clean daily close above this resistance could push toward the $7.37 52-week high. With 2026 pipeline catalysts and recent $16 analyst targets, the stage is set for a major trend continuation. Waiting for volume confirmation to validate the move. Giddy up!
0 · Reply
Bangra
Bangra Jan. 16 at 2:55 PM
$SLDB we have to break through 5.72 to be able to go further up.
0 · Reply
Quantumup
Quantumup Jan. 16 at 1:08 PM
Cantor reiterated $CAPR Overweight-$62 $EWTX $PTCT SRPT $DYN $SLDB Cantor said in its note: We received clarity on filing plans for deramiocel for DMD following the recent positive HOPE-3 Phase 3 data. The FDA saw the top-line data, CAPR is submitting the entirety of it in mid-February, and expects a filing acceptance decision 30 days after. We wouldn't be surprised if shares continue to climb up into a PDUFA date should this be accepted for review.
0 · Reply
biotech
biotech Jan. 16 at 9:03 AM
$SGMO $XBI Therapies to Watch in 1H 2026 $RGNX DMD Gene Therapy RGX-202 $RARE Glycogen Storage Disease Gene Therapy DTX401 $SLDB Friedreich Ataxia Gene Therapy SGT-212 $SGMO Fabry gene therapy isaralgagene civaparvove ( ST-920) https://www.cgtlive.com/view/therapies-watch-1h-2026
0 · Reply
pharmd2828
pharmd2828 Jan. 16 at 3:31 AM
$SLDB JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
1 · Reply
Olg59
Olg59 Jan. 15 at 7:18 PM
$SLDB Could no get under 5.70. However, entered at 5.75
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 15 at 5:14 PM
$SLDB Technicals are beginning to align with the strong fundamental outlook. Currently testing the upper trendline of a multi-month symmetrical triangle. As the price coils toward the apex, I’m watching for a high-volume breakout above the $6.00 level to confirm the next leg up. A clean daily close above resistance should trigger a push toward the $7.37 52-wk high. With the 2026 pipeline catalysts and recent $16 analyst targets, the setup for a major trend continuation is firmly in place. Watching for volume confirmation to validate the move. Giddy up.
1 · Reply
Latest News on SLDB
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 11:46 PM EST - 6 days ago

Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Jan 13, 2026, 4:15 PM EST - 6 days ago

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 4:15 PM EST - 7 days ago

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 8:05 AM EST - 8 days ago

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 14 days ago

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 4:15 PM EST - 14 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Dec 16, 2025, 4:51 PM EST - 4 weeks ago

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Dec 8, 2025, 8:00 AM EST - 6 weeks ago

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Dec 1, 2025, 8:00 AM EST - 7 weeks ago

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Nov 17, 2025, 8:00 AM EST - 2 months ago

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences to Participate at Upcoming Investor Conferences

Nov 11, 2025, 8:00 AM EST - 2 months ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Nov 6, 2025, 8:00 AM EST - 2 months ago

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Nov 3, 2025, 4:05 PM EST - 2 months ago

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 3 months ago

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Sep 25, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Sep 23, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Sep 23, 2025, 8:00 AM EDT - 4 months ago

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:28 PM EDT - 4 months ago

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 5 months ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

Jul 11, 2025, 3:02 PM EDT - 6 months ago

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 6 months ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 8 months ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 8 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 9 months ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 9 months ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 8, 2025, 4:50 PM EDT - 10 months ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 10 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 11 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 12:29 PM EST - 1 year ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 1 year ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 6:27 PM EST - 1 year ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 1 year ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 1 year ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 1 year ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Mar 13, 2024, 7:44 AM EDT - 2 years ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Olg59
Olg59 Jan. 20 at 4:50 PM
$SLDB Brake 6.00, then fly to 10.00 Under 5.70 great entry!
0 · Reply
Jonrenie
Jonrenie Jan. 20 at 9:51 AM
$SLDB keep an eye for more loading opportunities
0 · Reply
LeaRoss
LeaRoss Jan. 19 at 2:50 PM
$SLDB Watching for volume surge, breakout could fuel momentum
1 · Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 17 at 12:08 PM
$SLDB 📈 Technicals are starting to align with a strong fundamental story. Currently testing the upper trendline of a multi-month symmetrical triangle. If this helps, tap @QuantitativeTrading_ As price coils toward the apex, I’m watching for a high-volume breakout above $6.00 — a clean daily close above this resistance could push toward the $7.37 52-week high. With 2026 pipeline catalysts and recent $16 analyst targets, the stage is set for a major trend continuation. Waiting for volume confirmation to validate the move. Giddy up!
0 · Reply
Bangra
Bangra Jan. 16 at 2:55 PM
$SLDB we have to break through 5.72 to be able to go further up.
0 · Reply
Quantumup
Quantumup Jan. 16 at 1:08 PM
Cantor reiterated $CAPR Overweight-$62 $EWTX $PTCT SRPT $DYN $SLDB Cantor said in its note: We received clarity on filing plans for deramiocel for DMD following the recent positive HOPE-3 Phase 3 data. The FDA saw the top-line data, CAPR is submitting the entirety of it in mid-February, and expects a filing acceptance decision 30 days after. We wouldn't be surprised if shares continue to climb up into a PDUFA date should this be accepted for review.
0 · Reply
biotech
biotech Jan. 16 at 9:03 AM
$SGMO $XBI Therapies to Watch in 1H 2026 $RGNX DMD Gene Therapy RGX-202 $RARE Glycogen Storage Disease Gene Therapy DTX401 $SLDB Friedreich Ataxia Gene Therapy SGT-212 $SGMO Fabry gene therapy isaralgagene civaparvove ( ST-920) https://www.cgtlive.com/view/therapies-watch-1h-2026
0 · Reply
pharmd2828
pharmd2828 Jan. 16 at 3:31 AM
$SLDB JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
1 · Reply
Olg59
Olg59 Jan. 15 at 7:18 PM
$SLDB Could no get under 5.70. However, entered at 5.75
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 15 at 5:14 PM
$SLDB Technicals are beginning to align with the strong fundamental outlook. Currently testing the upper trendline of a multi-month symmetrical triangle. As the price coils toward the apex, I’m watching for a high-volume breakout above the $6.00 level to confirm the next leg up. A clean daily close above resistance should trigger a push toward the $7.37 52-wk high. With the 2026 pipeline catalysts and recent $16 analyst targets, the setup for a major trend continuation is firmly in place. Watching for volume confirmation to validate the move. Giddy up.
1 · Reply
Bangra
Bangra Jan. 15 at 4:05 PM
$SLDB It seems we're back on track.
0 · Reply
Olg59
Olg59 Jan. 15 at 2:54 PM
$SLDB Missed 5.65 as my entry was 5.60
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 15 at 2:14 PM
$SLDB Street support remains exceptionally strong following the recent PL milestones. Needham just reaffirmed their Buy rating with a $16 PT, suggesting the stock has roughly 175% runway from current levels. The analyst note highlights that the SGT-003 safety profile and microdystrophin expression data are clear differentiators. This reiteration, combined w/ the 2026 outlook, confirms that institutional confidence is building around Solid’s ability to execute. In my view, it signals they believe the market hasn't yet priced in the full value of the capsid platform, PL potential, and the accelerated approval potential for Duchenne.
1 · Reply
pharmd2828
pharmd2828 Jan. 14 at 8:10 PM
$SLDB in my humble opinion this is just a beginning after solid presentation yesterday and the guidelines for 2026 
1 · Reply
Bangra
Bangra Jan. 14 at 6:16 PM
$SLDB
0 · Reply
Jonrenie
Jonrenie Jan. 14 at 5:57 PM
$SLDB
0 · Reply
pharmd2828
pharmd2828 Jan. 14 at 5:21 PM
$SLDB shorts are going to get burnt ! 2026 guideline is so positive and sounds of a strong turning point in this gem!
0 · Reply
Olg59
Olg59 Jan. 14 at 5:14 PM
$AQST Move to $SLDB Will double!
1 · Reply
pharmd2828
pharmd2828 Jan. 14 at 5:13 PM
$SLDB 2026 will be very interesting for this small biotech! I believe the best investment for long-term! IMHO
0 · Reply
Bangra
Bangra Jan. 14 at 5:11 PM
$SLDB The next resistance is around USD 6.00. If this level is broken, the next stronger resistance could be at USD 6.20-6.24.
0 · Reply
The_Red_Fox
The_Red_Fox Jan. 14 at 5:05 PM
$SLDB Fireworks. Check.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 14 at 5:02 PM
$SLDB
0 · Reply